The archive · Bio & Materials · Strategic decision · 2022–2026
Metsera Bets on Monthly GLP-1; Pfizer Paid ~$10B
Metsera bet on ultra-long-acting GLP-1; after 14.1% weight loss data, Pfizer raised bid to ~$10B, closing 2025-11-13.
Metsera
What the business is
Metsera develops new drugs for weight loss and metabolic disease: it is developing injectable and oral nutrient-stimulating hormone (NuSH) analog peptides, with lead asset MET-097i being an ultra-long-acting GLP-1 targeting once-weekly or even once-monthly dosing; the pipeline also includes amylin analog MET-233i and two oral GLP-1 candidates.
Starting capital：Series A $290M (2024-04) + Series B $215M (2024-11); IPO raised about $275M (priced 2025-01-30, $18 per share).
How it started
In 2022, Arch Venture Partners and Population Health Partners founded Metsera during the biopharma funding winter, targeting next-generation weight-loss and metabolic-disease drugs; in 2024-04, it emerged from stealth with a $290M Series A, and in 2024-11 raised $215M in Series B; on 2025-01-30, it priced its IPO at $18 per share, and the next day listed on Nasdaq (纳斯达克) under MTSR, raising about $275M.
What happened
Pipeline core MET-097i is an ultra-long-acting GLP-1 (HALO platform, half-life about 380 hours): in 2025-09, results from the 239-participant VESPER-1 Phase 2b were released, with the highest dose of 1.2mg given weekly for 28 weeks achieving 14.1% placebo-corrected weight loss, individual subjects exceeding 26%, and only 2 participants discontinuing due to adverse events. On 2025-09-22, Pfizer first announced an acquisition at $47.50 per share (base value about $4.9B, plus up to $22.50 per share in milestone payments); on 11-07, it revised the offer to $65.60 per share in cash plus up to $20.65 in CVR, for a total equity value of about $10B, and on 11-13 the transaction was completed.
How it ended up
Acquired: Metsera was merged into Pfizer on 2025-11-13, becoming a wholly owned subsidiary and delisting; MET-097i was renamed PF-08653944 (PF'3944). The VESPER-3 monthly-dosing Phase 2b top-line results released in 2026-02 showed that the highest-dose group achieved 12.3% placebo-corrected weight loss over 28 weeks; Pfizer included the 9.6mg monthly maintenance dose in Phase 3 and planned about 10 Phase 3 trials.
Background
Metsera develops new drugs for weight loss and metabolic disease; lead asset MET-097i is an ultra-long-acting GLP-1 receptor agonist: the HALO lipidation platform extends the half-life to about 380 hours, targeting once-weekly or even once-monthly dosing, and the pipeline includes oral GLP-1 and amylin analog MET-233i.
The company was founded in 2022 by Arch Venture Partners and Population Health Partners during a funding winter; in 2024-04, it emerged from stealth with a $290M Series A, and in 2024-11 raised $215M in Series B; on 2025-01-30, it priced its IPO at $18 per share, and the next day listed on Nasdaq under MTSR, raising about $275M.
In 2025-09, Metsera released top-line results from the 239-participant VESPER-1 Phase 2b: MET-097i at the highest dose of 1.2mg given weekly for 28 weeks achieved 14.1% placebo-corrected weight loss, individual subjects exceeded 26%, and only 2 participants discontinued due to adverse events. On 09-22, Pfizer announced an acquisition at $47.50 per share (base value about $4.9B, plus up to $22.50 per share in milestones); on 11-07, it revised the offer to $65.60 per share in cash plus up to $20.65 in CVR, for a total equity value of about $10B, and on 11-13 the deal closed.
After the acquisition, MET-097i was renamed PF-08653944 (PF'3944) and became the anchor of Pfizer's weight-loss pipeline: the 2026-02 VESPER-3 Phase 2b top-line showed that, after switching to monthly dosing, the highest-dose group achieved 12.3% placebo-corrected weight loss over 28 weeks; Pfizer accordingly included the 9.6mg monthly maintenance dose in Phase 3 and planned about 10 Phase 3 trials.
What has to be true
- Clear differentiation: convenient dosing (weekly to monthly, injection to oral) addresses adherence pain point.
- Fast clinical cadence: stealth 2024, listed 2025, Phase 2b data September; milestones drove valuation.
- Platform assets more valuable: Pfizer bought MET-097i plus HALO/MOMENTUM platforms, willing to pay premium.
- Clear buyer need: Pfizer's oral GLP-1 failed twice; acquisition only fast path, so bid reached ~$10B.
What can be applied
Differentiate via dosing frequency: half-life engineering plus monthly dosing rewrites user experience; prove quantifiable metric, and valuation follows.
Aftermath
As of 2026-09-01: Pfizer completed the acquisition of Metsera on 2025-11-13, and Metsera was delisted and integrated into Pfizer; MET-097i (PF-08653944 / PF'3944), as the core of Pfizer's weight-loss pipeline, is proceeding as planned with about 10 Phase 3 trials (VESPER-4/5/6, etc.) after positive VESPER-3 monthly-dosing top-line results, including a 9.6mg monthly maintenance dose regimen.
Sources
- Metsera Announces Pricing of Initial Public Offering
- Pfizer amps up push into obesity treatments with $4.9 billion deal for Metsera
- Metsera, Inc. Form 10-Q for the quarter ended September 30, 2025
- Pfizer Inc. Form 8-K (completion of Metsera acquisition)
- Once-monthly GLP-1 confers up to 12.3% weight loss at 28 weeks for adults with obesity
- 辉瑞73亿美元押注减重药 能否挑战“双雄”时代格局
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card